Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936611 · ClinicalTrials.gov registry record · Phase 2
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00936611 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 39 participants.
The verdict
NCT00936611, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the same activity in people with Waldenstrom's Macroglobulinemia. This drug has been used in research for the treatment of other types of cancer, such as multiple myeloma.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936611
The ClinicalTrials.gov registry entry for NCT00936611 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT00936611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936611 about?
NCT00936611 is a clinical study titled "LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia". The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the...
What is the current status of trial NCT00936611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2009-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00936611?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00936611?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.